These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 25956465)

  • 1. Metabolic consequences of oncogenic IDH mutations.
    Parker SJ; Metallo CM
    Pharmacol Ther; 2015 Aug; 152():54-62. PubMed ID: 25956465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IDH mutations in cancer and progress toward development of targeted therapeutics.
    Dang L; Yen K; Attar EC
    Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reductive carboxylation and 2-hydroxyglutarate formation by wild-type IDH2 in breast carcinoma cells.
    Smolková K; Dvořák A; Zelenka J; Vítek L; Ježek P
    Int J Biochem Cell Biol; 2015 Aug; 65():125-33. PubMed ID: 26007236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.
    Sharma H
    Curr Top Med Chem; 2018; 18(6):505-524. PubMed ID: 29773061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitor potency varies widely among tumor-relevant human isocitrate dehydrogenase 1 mutants.
    Avellaneda Matteo D; Wells GA; Luna LA; Grunseth AJ; Zagnitko O; Scott DA; Hoang A; Luthra A; Swairjo MA; Schiffer JM; Sohl CD
    Biochem J; 2018 Oct; 475(20):3221-3238. PubMed ID: 30249606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isocitrate Dehydrogenase Mutations in Cancer: Mechanisms of Transformation and Metabolic Liability.
    Gunn K; Losman JA
    Cold Spring Harb Perspect Med; 2024 May; 14(5):. PubMed ID: 38191174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization.
    Ward PS; Lu C; Cross JR; Abdel-Wahab O; Levine RL; Schwartz GK; Thompson CB
    J Biol Chem; 2013 Feb; 288(6):3804-15. PubMed ID: 23264629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting isocitrate dehydrogenase (IDH) in cancer.
    Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
    Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic dysregulation in cancers by isocitrate dehydrogenase 2 (IDH2).
    Nayarisseri A; Bandaru S; Khan A; Sharma K; Bhrdwaj A; Kaur M; Ghosh D; Chopra I; Panicker A; Kumar A; Saravanan P; Belapurkar P; Mendonça Junior FJB; Singh SK
    Adv Protein Chem Struct Biol; 2024; 141():223-253. PubMed ID: 38960475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
    Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
    J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
    Han CH; Batchelor TT
    Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
    Ward PS; Patel J; Wise DR; Abdel-Wahab O; Bennett BD; Coller HA; Cross JR; Fantin VR; Hedvat CV; Perl AE; Rabinowitz JD; Carroll M; Su SM; Sharp KA; Levine RL; Thompson CB
    Cancer Cell; 2010 Mar; 17(3):225-34. PubMed ID: 20171147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
    Showalter MR; Hatakeyama J; Cajka T; VanderVorst K; Carraway KL; Fiehn O;
    Elife; 2017 Jun; 6():. PubMed ID: 28653623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation.
    Molenaar RJ; Radivoyevitch T; Maciejewski JP; van Noorden CJ; Bleeker FE
    Biochim Biophys Acta; 2014 Dec; 1846(2):326-41. PubMed ID: 24880135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
    Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H
    PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.
    Ward PS; Cross JR; Lu C; Weigert O; Abel-Wahab O; Levine RL; Weinstock DM; Sharp KA; Thompson CB
    Oncogene; 2012 May; 31(19):2491-8. PubMed ID: 21996744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome.
    Reitman ZJ; Jin G; Karoly ED; Spasojevic I; Yang J; Kinzler KW; He Y; Bigner DD; Vogelstein B; Yan H
    Proc Natl Acad Sci U S A; 2011 Feb; 108(8):3270-5. PubMed ID: 21289278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.
    Intlekofer AM; Shih AH; Wang B; Nazir A; Rustenburg AS; Albanese SK; Patel M; Famulare C; Correa FM; Takemoto N; Durani V; Liu H; Taylor J; Farnoud N; Papaemmanuil E; Cross JR; Tallman MS; Arcila ME; Roshal M; Petsko GA; Wu B; Choe S; Konteatis ZD; Biller SA; Chodera JD; Thompson CB; Levine RL; Stein EM
    Nature; 2018 Jul; 559(7712):125-129. PubMed ID: 29950729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling.
    M Gagné L; Boulay K; Topisirovic I; Huot MÉ; Mallette FA
    Trends Cell Biol; 2017 Oct; 27(10):738-752. PubMed ID: 28711227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH2 compensates for IDH1 mutation to maintain cell survival under hypoxic conditions in IDH1‑mutant tumor cells.
    Zhang Y; Lv W; Li Q; Wang Q; Ru Y; Xiong X; Yan F; Pan T; Lin W; Li X
    Mol Med Rep; 2019 Aug; 20(2):1893-1900. PubMed ID: 31257503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.